| ||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:777.)
© 2005 American Heart Association, Inc.
Issue Highlights
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
 |
UTILITY OF CARDIAC MAGNETIC RESONANCE IMAGING IN THE DIAGNOSIS OF HYPERTROPHIC CARDIOMYOPATHY, by Rickers et al. |
|---|
The diagnosis of hypertrophic cardiomyopathy (HCM) traditionally requires echocardiographic demonstration of hypertrophy without inciting cause. However, there are limitations to echocardiography in terms of resolution of particular ventricular regions as well as technically challenging patients for obtaining high-quality images. These points are of particular importance when the diagnosis of HCM is in question and wall thickness measures take on great significance. Cardiac magnetic resonance (CMR) imaging overcomes many of these limitations. In this issue of Circulation, Rickers and colleagues perform echocardiograms and CMR imaging in patients referred for diagnosis of HCM. A small but significant minority of patients had CMR images with wall thickness diagnostic for HCM in the absence of echocardiographic evidence, and thickness of the anterolateral wall was on average significantly greater on CMR imaging than on echocardiography. These data strongly suggest that the approach to the diagnosis of HCM in the contemporary era should involve CMR imaging, particularly when diagnosis is challenging. See p 855.
|
DIFFERENTIAL INFLUENCE OF CHEMOKINE RECEPTORS CCR2 AND CXCR3 IN DEVELOPMENT OF ATHEROSCLEROSIS IN VIVO, by Veillard et al. |
|---|
There can be no question that inflammation plays an important role in both the development and clinical manifestations of atherosclerosis. Nevertheless, our understanding of precisely how inflammation modulates the atherosclerotic process remains naïve. In this issue, Veillard and coworkers provide us with important evidence that not all immune modulation has predictable effects on atherosclerosis. These investigators found that some chemokine receptors are only important in the early stages of atherosclerosis but not in more mature stages of the disease. These data have important implications for designing immune-modulating therapies for human
Related Articles:
Circulation 2005 112: 855-861.
Circulation 2005 112: e76-e78.
Circulation 2005 112: e79-e80.
Circulation 2005 112: e81.
Circulation 2005 112: e82-e83.
Circulation 2005 112: 870-878.
Circulation 2005 112: 879-884.